AegirBio AB (publ) (AEGIR.ST)
AegirBio AB (publ) operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Lund, SE. The stock last traded at $0.43, up 3.88% on the session, giving a market capitalisation of $15.4M. Its beta of 2.75 implies it has historically moved more than the broad market.
AegirBio AB (publ) is a diagnostics firm established in 2019 in Lund, Sweden. The company specializes in developing and commercializing tests primarily aimed at monitoring the dosage of biological drugs. Their efforts are concentrated on therapeutic drug monitoring for biologic therapies across various conditions, including multiple sclerosis, different types of cancer, and autoimmune diseases. Among their offerings are moNATor, a pioneering laboratory test designed for dose monitoring in multiple sclerosis for both medical professionals and patients, and Viraspec, a saliva-based test kit for COVID-19 detection.
AegirBio AB (publ) is most often compared with the following Healthcare names: